PDCD1 and breast carcinoma: Although there are many clinical studies confirming that the benefits of anti-PD-1/anti-PD-L1 therapies have a certain clinical effect on advanced breast cancer, we can still see that a considerable proportion of patients have shown little clinical efficacy.